Agenus to Present at the 4th Annual Cancer Immunotherapy Conference
March 26 2014 - 7:00AM
Business Wire
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein,
MD, PhD, Chief Scientific Officer of Agenus, will be presenting on
Agenus’ checkpoint modulator portfolio and immuno-oncology strategy
at the 4th Annual Cancer Immunotherapy Conference at the New York
Academy of Medicine in New York City. On March 27, 2014, a
presentation on Checkpoint Modulators is scheduled for 8:30 am
Eastern Time and a corporate presentation is scheduled for 2:15 pm
Eastern Time.
Additionally, Dr. Stein will be
participating on several panels, including:
9:30 am -10:15 am: Emerging Role of
Combination Tumor Immunotherapies
11:45 pm -12:30 pm: Autologous
Immunotherapies
4:00 pm - 4:30 pm: Immunotherapies for Solid Tumors
The corporate presentation will be webcast and accessible from
the company’s website at www.agenusbio.com/webcast/.
About Agenus
Agenus is a biopharmaceutical company developing a portfolio of
immuno-oncology candidates, including checkpoint modulators, heat
shock protein vaccines and adjuvants. The company’s proprietary
discovery engine Retrocyte Display® is designed to rapidly generate
high quality therapeutic antibody drug candidates using a
high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. A portfolio of
checkpoint modulator programs, including GITR, OX40 agonists and
CTLA-4, PD-1, LAG-3 and TIM-3 antagonists, is advancing in
preclinical development. The company’s heat shock protein vaccines
for cancer and infectious disease are in Phase 2 studies. Agenus’
QS-21 Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and Janssen and includes several candidates in
Phase 3 trials. Among Agenus and its partners, 23 programs are in
clinical development. For more information, please visit
www.agenusbio.com, or connect with the company on Facebook,
LinkedIn, Twitter and Google+.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding research and development activities
of the Company and its licensees. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our Annual Report on Form 10-K filed with the Securities
and Exchange Commission for the period ended December 31, 2013.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
QS-21 Stimulon and Retrocyte Display are registered trademarks
of Agenus and its subsidiaries.
Agenus Inc.Media and Investor Contact:Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relationsand Corporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024